News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
551,326 Results
Type
Article (46582)
Company Profile (119)
Press Release (504614)
Multimedia
Podcasts (142)
Webinars (19)
Section
Business (145712)
Career Advice (2419)
Deals (28113)
Drug Delivery (141)
Drug Development (68499)
Employer Resources (158)
FDA (15970)
Job Trends (12061)
News (265493)
Policy (29902)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2315)
Academic (1)
Accelerated approval (34)
Adcomms (36)
Allergies (137)
Alliances (36142)
ALS (163)
Alzheimer's disease (1711)
Antibody-drug conjugate (ADC) (314)
Approvals (16114)
Artificial intelligence (498)
Autoimmune disease (158)
Automation (33)
Bankruptcy (312)
Best Places to Work (9192)
BIOSECURE Act (23)
Biosimilars (191)
Biotechnology (69)
Bladder cancer (157)
Brain cancer (54)
Breast cancer (588)
Cancer (4532)
Cardiovascular disease (410)
Career advice (2046)
Career pathing (39)
CAR-T (259)
CDC (59)
Celiac Disease (1)
Cell therapy (720)
Cervical cancer (35)
Clinical research (58823)
Collaboration (1484)
Company closure (4)
Compensation (1154)
Complete response letters (74)
COVID-19 (2718)
CRISPR (86)
C-suite (785)
Cystic fibrosis (141)
Data (5780)
Decentralized trials (2)
Denatured (32)
Depression (144)
Diabetes (480)
Diagnostics (5539)
Digital health (37)
Diversity (7)
Diversity, equity & inclusion (43)
Drug discovery (219)
Drug pricing (221)
Drug shortages (33)
Duchenne muscular dystrophy (238)
Earnings (62259)
Editorial (66)
Employer branding (20)
Employer resources (142)
Events (81855)
Executive appointments (893)
FDA (19036)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (20)
Funding (1272)
Gene editing (192)
Generative AI (43)
Gene therapy (607)
GLP-1 (1066)
Government (4195)
Grass and pollen (8)
Guidances (376)
Healthcare (14882)
HIV (59)
Huntington's disease (49)
IgA nephropathy (84)
Immunology and inflammation (288)
Immuno-oncology (59)
Indications (99)
Infectious disease (2978)
Inflammatory bowel disease (182)
Inflation Reduction Act (14)
Influenza (108)
Intellectual property (236)
Interviews (453)
IPO (14133)
IRA (58)
Job creations (3173)
Job search strategy (1672)
JPM (67)
Kidney cancer (17)
Labor market (83)
Layoffs (618)
Leadership (40)
Legal (7015)
Liver cancer (90)
Longevity (12)
Lung cancer (598)
Lymphoma (354)
Machine learning (40)
Management (52)
Manufacturing (734)
MASH (167)
Medical device (11580)
Medtech (11624)
Mergers & acquisitions (14975)
Metabolic disorders (1315)
Multiple sclerosis (144)
NASH (22)
Neurodegenerative disease (323)
Neuropsychiatric disorders (98)
Neuroscience (2909)
Neurotech (1)
NextGen: Class of 2026 (4996)
Non-profit (3192)
Now hiring (31)
Obesity (660)
Opinion (277)
Ovarian cancer (153)
Pain (189)
Pancreatic cancer (218)
Parkinson's disease (275)
Partnered (26)
Patents (477)
Patient recruitment (458)
Peanut (54)
People (44190)
Pharmaceutical (33)
Pharmacy benefit managers (32)
Phase 1 (17653)
Phase 2 (25455)
Phase 3 (20850)
Pipeline (4988)
Policy (333)
Postmarket research (2207)
Preclinical (7140)
Press Release (28)
Prostate cancer (239)
Psychedelics (55)
Radiopharmaceuticals (244)
Rare diseases (883)
Real estate (4301)
Recruiting (65)
Regulatory (23168)
Reports (40)
Research institute (2114)
Resumes & cover letters (404)
Rett syndrome (27)
RNA editing (16)
RSV (73)
Schizophrenia (152)
Series A (216)
Series B (177)
Service/supplier (8)
Sickle cell disease (95)
Special edition (25)
Spinal muscular atrophy (139)
Sponsored (46)
Startups (2787)
State (1)
Stomach cancer (20)
Supply chain (104)
Tariffs (101)
The Weekly (109)
Vaccines (1094)
Venture capital (96)
Weight loss (465)
Women's health (73)
Worklife (22)
Date
Today (141)
Last 7 days (530)
Last 30 days (1938)
Last 365 days (28244)
2026 (3115)
2025 (28396)
2024 (31398)
2023 (34982)
2022 (45058)
2021 (48498)
2020 (45510)
2019 (36209)
2018 (27395)
2017 (27803)
2016 (25803)
2015 (27973)
2014 (21774)
2013 (17791)
2012 (18963)
2011 (19381)
2010 (17504)
Location
Africa (686)
Alabama (66)
Alaska (6)
Arizona (231)
Arkansas (10)
Asia (32349)
Australia (5666)
California (10394)
Canada (2504)
China (914)
Colorado (407)
Connecticut (459)
Delaware (303)
Europe (78951)
Florida (1575)
Georgia (316)
Hawaii (4)
Idaho (39)
Illinois (738)
India (54)
Indiana (425)
Iowa (22)
Japan (406)
Kansas (105)
Kentucky (25)
Louisiana (19)
Maine (73)
Maryland (1285)
Massachusetts (7535)
Michigan (266)
Minnesota (550)
Mississippi (5)
Missouri (118)
Montana (12)
Nebraska (22)
Nevada (111)
New Hampshire (60)
New Jersey (2803)
New Mexico (15)
New York (2691)
North Carolina (1347)
North Dakota (7)
Northern California (5157)
Ohio (278)
Oklahoma (15)
Oregon (34)
Pennsylvania (1999)
Puerto Rico (18)
Rhode Island (32)
South America (1045)
South Carolina (64)
South Dakota (1)
Southern California (4041)
Tennessee (151)
Texas (1549)
United States (36369)
Utah (262)
Virginia (242)
Washington D.C. (73)
Washington State (827)
West Virginia (4)
Wisconsin (109)
Wyoming (1)
551,326 Results for "stalicla s a".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs
June 30, 2025
·
3 min read
Business
STALICLA Appoints Dr. Thomas Blaettler, MD
STALICLA SA announced the appointment of Thomas Blaettler, to the position of Chief Medical Officer.
April 11, 2024
·
3 min read
Drug Development
STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder
STALICLA SA announces the First Patient First Visit for the company’s drug-drug interaction study of STP7, an mGluR5 negative allosteric modulator, licensed to STALICLA by Novartis.
May 2, 2024
·
2 min read
Drug Development
STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines
STALICLA SA announced the publication of a landmark phase 1b study with STP1, a novel combination therapy tailored for the treatment of a clinically and biologically defined subgroup of patients with autism spectrum disorder, named ASD Phenotype 1.
June 27, 2024
·
3 min read
Stalicla Secures $17.4 Million in Series B Financing to Propel Precision Neuro Advancements
Stalicla SA announces the successful completion of the first closing of its Series B financing round, securing $17.4 million.
January 16, 2024
·
2 min read
Business
STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
July 10, 2024
·
2 min read
Business
STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD
STALICLA and Firefly Neuroscience today announced a partnership to further validate EEG-based biomarkers in biologically enriched subgroups of patients with Autism Spectrum Disorder (ASD).
March 27, 2023
·
5 min read
Alzheimer’s disease
Biogen’s Much Anticipated Tau Readout in Alzheimer’s Will Spur More Questions
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market.
February 9, 2026
·
4 min read
·
Annalee Armstrong
STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment
STALICLA SA announced that it has entered into an exclusive in-licensing agreement with Novartis to develop mavoglurant as a treatment for substance-use disorder and neurodevelopmental disorders.
January 9, 2023
·
3 min read
STALICLA to in-license SFX-01 from Evgen for neurodevelopment disorder indications
STALICLA SA today announced the worldwide in-licensing of SFX-01 from Evgen Pharma plc (Evgen) in neurodevelopmental disorders and schizophrenia, with a first indication for a biologically-characterized subgroup of patients with Autism Spectrum Disorder (ASD).
October 10, 2022
·
4 min read
1 of 55,133
Next
